ISSN: 1859 - 2872
The initial results of neoadjuvant concurrent chemoradiotherapy using intensity modulated radiation therapy technique in stage II-III middle-lower third esophageal cancer
Main Article Content
Keywords
Abstract
Objective: To assess the intial treatment results of neoadjuvant chemoradiation using intensity modulated radiation therapy (IMRT) technique followed by surgery in the middle and lower thirds, stage II-III esophageal cancer patients at the 108 Military Central Hospital. Subject and method: A retrospective study on 83 patients with middle and lower, stage II-III esophageal cancer who received 41.4Gy in 23 fractions concurrent chemoradiation with weekly paclitaxel/carboplatin and followed by surgery. Result: The average age was 57 years old. The most common symptom was dysphagia with 91.6% patients and there were 80.7% patients in stage III (AJJC8). The pathology complete response was 37.3% (pT0N0). Adverse effects including fatigue, esophageal mucositis, and leukopenia, most of which were in grade 1-2. Conclusion: Preoperative chemoradiation using IMRT is an effective treatment method for stgage II-III esophageal cancer patients with acceptable side effects.
Article Details
References
2. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J. Clin. Oncol 27(6) 851-856. doi: 10.1200/JCO.2008.17.0506.
3. Tu L, Sun L, Xu Y et al (2013) Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma. Radiat. Oncol 8(1): 75. doi: 10.1186/1748-717X-8-75.
4. Japan Esophageal Society (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part II and III’, Esophagus 14(1): 37-65. doi: 10.1007/s10388-016-0556-2.
5. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11): 2680-2686.
6. Nguyễn Đức Lợi (2015) Đánh giá hiệu quả phác đồ hoá xạ trị đồng thời và một số yếu tố tiên lượng ung thư biểu mô vẩy thực quản giai đoạn III, IV tại Bệnh viện K. Luận án tiến sĩ y học, Luận án tiến sĩ y học, Trường Đại học Y Hà Nội.
7. van Hagen P, Hulshof MC, van Lanschot JJ, et al (2012) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N. Engl. J. Med 366(22): 2074-2084. doi: 10.1056/NEJMoa1112088.
8. Lloyd S and Chang BW (2014) Current strategies in chemoradiation for esophageal cancer. J. Gastrointest. Oncol 5(3): 156-165. doi: 10.3978/j.issn.2078-6891.2014.033.
9. Rice TW, Patil DT, and Blackstone EH (2017) 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann. Cardiothorac. Surg 6(2): 119-130. doi: 10.21037/acs.2017.03.14.
10. Fenkell L, Kaminsky I, Breen S, Huang S, Van Prooijen M, and Ringash J (2008) Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother. Oncol 89(3): 287-291. doi: 10.1016/j.radonc.2008.08.008.
11. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z (2012) Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int. J. Radiat. Oncol 84(5): 1078-1085. doi: 10.1016/j.ijrobp.2012.02.015.
12. Han J, Wang Z, and Liu C (2021) Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: A meta-analysis. Future Oncol 17(17): 2257–2274. doi: 10.2217/fon-2021-0021.
13. Xu C and Lin SH (2016) Esophageal cancer: comparative effectiveness of treatment options. Comp. Eff. Res 6: 1-12. doi: 10.2147/CER.S73805.
Article Sidebar
